


## Abstract

Recombinant protein production is an essential step in the development of many novel, life-saving therapies and diagnostics. Stable cell line development enables consistent protein yields and product quality, but the process is lengthy, costly and time-consuming. Transient protein expression could be a viable alternative to stable cell line development producing material for pre-clinical development and early clinical trials.

To realize the potential of transiently expressed protein, very large quantities of transfected cells are required. MaxCyte's ExPERT VLx™ enables the transfection of up to 200 billion cells in under 30 minutes. Cell concentration and buffer exchange prepare cells for electroporation; one solution is tangential flow filtration (TFF), which offers gentle processing that is scalable, fast and easy to use. In collaboration with Repligen, we developed an optimized process using the KTF-600 KrosFlo® system and hollow fiber TFF devices to deliver CHO cells in MaxCyte electroporation buffer, at the required concentration of  $2 \times 10^8$  cells/mL.

## Experimental Design



### Seed Train

CHO Seed Train (20L) in a bioreactor

### Cell Concentration and Buffer Exchange

Cells were concentrated to 700 mL in MaxCyte EP buffer by Repligen TFF

### Electroporation


1 mL cell aliquot was transfected with plasmid DNA

### Resting

Transfected cells rested and were cultured for 24 hours

### Analysis

Transfection efficiency was assessed by Flow Cytometry



**Figure 1. Cell concentration and buffer exchange yields healthy, electroporation-ready cells which can be efficiently transfected.** CHO cells from the seed train at  $8 \times 10^6$  cells/mL in growth media were concentrated to  $2 \times 10^8$  cells/mL in MaxCyte electroporation buffer. Vi-CELL™ analysis confirmed that high cell viability was maintained throughout. Cells were transfected with 300µg/mL of pGFP DNA using the MaxCyte VLx. Transfection efficiency was assessed 24 hours post electroporation; 99% of transfected cells expressed GFP.

### Summary

- This proof-of-concept study confirms that Repligen's KTF-600 KrosFlo® and hollow fiber TFF devices provide a gentle, efficient method for large-volume cell concentration and buffer exchange prior to electroporation.
- The concentrated cell volume achieved enables electroporation of up to 200 billion cells, in a single run on the MaxCyte VLx, for high-efficiency transfection in under 30 minutes.
- Repligen's KTF-600 KrosFlo system can be connected to the MaxCyte VLx in a sterile manner for a fully closed process.

Corresponding Authors: Mike Bransby; [mbransby@repligen.com](mailto:mbransby@repligen.com); Repligen Corporation, Tel: (626) 644-6812 and James Brady; [jamesb@maxcyte.com](mailto:jamesb@maxcyte.com); MaxCyte, Inc., Tel: (301) 944-1700



© 2022 MaxCyte, Inc. All rights reserved. MaxCyte®, MaxCyte ATx®, MaxCyte GT®, MaxCyte STx®, MaxCyte VLx®, Flow Transfection®, Flow Electroporation®, Any Cell, Any Molecule, Any Scale®, CARMA®, eexpert®, ATx®, GTx® and STx® ExPERT ATx®, ExPERT GTx®, ExPERT STx®, are trademarks of MaxCyte, Inc., registered in the U.S. Patent and Trademark Office. MaxCyte GTx™, MaxCyte STx™, ExPERT VLx™, ExPERT™, ATx™, GTx™, STx™, VLx™, VLx™, MaxCyte CARMA™ and CARMA Cell Therapies™ are trademarks of MaxCyte, Inc. Repligen™ and KrosFlo™ are trademarks of Repligen Corporation, registered in the U.S. Patent and Trademark Office. Vi CELL is a registered trademark of Beckman Coulter, Inc. in the United States and other countries.